Structured evidence table for Green Tea Body Composition Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Green Tea Body Composition Randomized Trial | Experimental studies provide substantial biological plausibility, while epidemiological studies have frequently associated habitual tea consumption with favorable cardiovascular outcomes. | 3 | Liu Rong (2026) | Tea consumption and cardiovascular risk and outcomes: mechanistic insights, epidemiological evidence, and clinical implications |
| Green Tea Body Composition Randomized Trial | However, these findings arise from heterogeneous evidence streams—including preclinical experiments, trials of surrogate risk markers, observational cohorts, and genetic analyses—and therefore differ substantially in their ability to support causal inference. | 3 | Liu Rong (2026) | Tea consumption and cardiovascular risk and outcomes: mechanistic insights, epidemiological evidence, and clinical implications |
| Green Tea Body Composition Randomized Trial | Such heterogeneity provides a rationale for exploring individualized tea-consumption strategies, but current evidence is insufficient to support disease-specific tea selection or therapeutic dosing. | 3 | Liu Rong (2026) | Tea consumption and cardiovascular risk and outcomes: mechanistic insights, epidemiological evidence, and clinical implications |
| Green Tea Body Composition Randomized Trial | 1 2 Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide (). | 3 | Liu Rong (2026) | Tea consumption and cardiovascular risk and outcomes: mechanistic insights, epidemiological evidence, and clinical implications |
| Green Tea Body Composition Randomized Trial | Second, mechanistic findings from cells and rodents are frequently discussed alongside human outcomes without distinguishing the evidence level or physiologically achievable exposure. | 3 | Hu Yangxian (2026) | Tea Bioactive Compounds in Obesity Prevention and Management: Processing-Dependent Composition, Molecular Mechanisms, Human Evidence, and Translational Challenges |
| Green Tea Body Composition Randomized Trial | In cultured human subcutaneous preadipocytes and adipocytes, a white-tea extract reduced triglyceride incorporation, increased glycerol release, and downregulated peroxisome proliferator-activated receptor γ (PPARγ), CCAAT/enhancer-binding protein α (C/EBPα), and sterol regulatory element-binding protein 1c (SREBP-1c), indicating inhibition of adipogenesis and stimulation of lipolysis []. | 3 | Hu Yangxian (2026) | Tea Bioactive Compounds in Obesity Prevention and Management: Processing-Dependent Composition, Molecular Mechanisms, Human Evidence, and Translational Challenges |
| Green Tea Body Composition Randomized Trial | Such studies remain valuable for identifying targets, but they should be interpreted as proof of biological possibility rather than evidence that ordinary tea consumption reproduces the same intracellular concentration. | 3 | Hu Yangxian (2026) | Tea Bioactive Compounds in Obesity Prevention and Management: Processing-Dependent Composition, Molecular Mechanisms, Human Evidence, and Translational Challenges |
| Green Tea Body Composition Randomized Trial | 1 2 3 4 Obesity results from sustained perturbations in energy intake, substrate partitioning, adipose-tissue biology, neuroendocrine signaling, and environmental exposures rather than from a single behavioral cause. | 3 | Hu Yangxian (2026) | Tea Bioactive Compounds in Obesity Prevention and Management: Processing-Dependent Composition, Molecular Mechanisms, Human Evidence, and Translational Challenges |
Source documents